Hypoxia modulation vs. chemotherapy and tumor shrinkage on early response assessment in diffuse large B-cell lymphoma
Abstract
Background: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy remains the standard of first-line treatment for diffuse large B-cell lymphoma (DLBCL). Up to 40% of DLBCL is characterized by relapse and refractory after treatment. Preliminary study reported Hypoxia-inducible factor-1 (HIF-1 ) overexpression in 88.5% of DLBCL tumors in the Dr. Kariadi Hospital. Moreover, the role of hypoxia and HIF-1 has previously never been explored in DLBCL.
Objectives: To evaluate the effect of hypoxia modulation to increased chemotherapeutic response in DLBCL.
Methods: Single blind randomized control study was performed, with pre-test and post-test control group design.
Research sampling consisted of DLBCL patients. The inclusion criteria include newly diagnosed DLBCL with HIF-1 overexpression and randomized to receive hypoxia modulation consisting of carbogen inhalation and nicotinamide administration, before R-CHOP chemotherapy. The tissue biopsy, histopathology and immunohistochemical studies were done. Chemotherapeutic responses were evaluated after 10-14 days following the first cycle of R-CHOP chemotherapy.
Results: Out of twenty-six DLBCL participants with HIF-1 overexpression, there were 20 participants who completed the research protocol: 10 participants each in the intervention and control group. Demographic, clinicopathological, laboratory and disease characteristics were not statistically different between the two research groups (p>0.05). Baseline tumor volume to be evaluated was also considered equal (172.3 cm3 vs. 152.8 cm3, p=0.597). Following the carbogen inhalation and nicotinamide administration, serum HIF-1 and lactate reduction can be observed. There was also a significant tumor volume shrinkage in both the intervention and control (mean –85.7 cm3 vs. –118.27 cm3) group, though the reduction was not statistically different (Delta 58.85% vs. 65.63%, p=0.474).
Conclusion: The addition of hypoxia modulation to R-CHOP chemotherapy for DLBCL has shown beneficial effects on both serum HIF-1 and lactate concentration. However, the benefits did not correlate to increase a better tumor response compared to the control group.
References
Reksodiputro AH. Multicentre epidemiology and survival study of B-cell non Hodgkin lymphoma patients in Indonesia. J Blood Disord Transf. 2015;6:2. doi: 10.4172/2155-9864.1000257
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. International Agency for Research on Cancer: Lyon, 2008.
Sangaletti S, Iannelli F, Zanardi F, Cancila V, Portararo P, Botti L, et al. Intra-tumor Heterogenecity of diffuse large B-cell lymphoma involves the induction of diversified strome-tumour interfaces. EBioMedicine. 2020;61:103055.
Tilly H, da Silva MG, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v116-25.
Zelenetz AD, Gordon LE, Chang JE, Christian, B, Abramson JS, Advani, RH, et al. NCCN clinical practice guidelines in oncology (NCCN guidelines) Insights: B-cell lymphomas. Version 5. 2021. J Natl Compr Canc Netw. 2021;19(11):1218-30.
Gonzalez-Barca E, Coronado M, Martin A, Montalbán C, Montes-Moreno S, Panizo C, et al. for the Spanish Lymphoma Group (GELTAMO). Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. Oncotarget. 2018;9 (64):32383-99.
Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5): 120-9.
Cancer chemotherapy handbook. Brighton D, Wood M, editor. The Royal Marsden hospital handbook of cancer chemotherapy. Elsevier, 2005.
Hammond EM, Giaccia AJ. Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers? Clin Cancer Res. 2006;12:5007–9.
Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P,et al. PD-L1 is a novel direct target of HIF-1α lpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781–90.
Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-40.
Pangarsa EA, Wuryantoro P, Naibaho RM, Setiawan B, Santosa D, Istiadi H, et al. Preliminary study of hypoxia markers in diffuse large B-cell lymphoma. Mol Clin Oncol. 2022;17(3):140. doi: 10.3892/mco.2022.2573
Liu C, Liu L. Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma. Front Genet. 2021;13:037716. doi: 10.3389/fgene.2022.1037716
Teicher BA, Holden SA, Al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity to putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50:3339-44.
Wei Y, Zeng H, Wei X, Huang W, Song J, Zheng J, et al. HIF-1α regulating the chemoresistance by upregulating the expression of xCT and GCLM in the diffuse large B-cell lymphoma. Blood 2019;134(Suppl_1):5236. doi: 10.1182/blood-2019-127612
Evens AM, Schumacker PT, Helenowski IB, Singh ATK, Dokic D, Keswani A, et al. Hypoxia inducible factor alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol. 2008;141:676-80.
Evens AM, Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, et al. Hypoxia-inducible factor-1α expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2010;28:1017-24.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 Jan 1;103(1):275-82. doi: 10.1182/blood-2003-05-1545. PMID: 14504078.
Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R, et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracyl delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res. 2006;12 (10):3115-23.
Siemann DW, Hill RP, Bush RS. The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Bio Phys. 1977;2(9-10):903-11.
Wu X, Pertovaara H, Korkola P, Vornanen M, Eskola H, Kellokumpu-Lehtinen PL. Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012 Mar;53(3):400-5. doi:10.3109/10428194.2011.622420. PMID: 21913807.
Bronchud MH. The importance of dose: lymphomas as a model of chemosensitive malignancies. Eur J Cancer. 1993; 29(Suppl. 5):S17-22.
Moghbel MC, Mittra E, Gallamini A, Niederkohr R, Chen DL, Zukotynski K et al. Response assessment criteria and their applications in lymphoma: part 2. J Nucl Med. 2019;58:13-22. doi: 10.2967/jnumed.116.184242
Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845-53.
Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 2023;8:70.
Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8(3):180-92.
Matolay O, Méhes G. Sustain, Adapt, and Overcome-Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia. Front Oncol. 2019 Nov 21;9:1277. doi: 10.3389/fonc.2019.01277
Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8(4):S62-7.
Xu R, Wang F, Yang H, Wang Z. Action sites and clinical applications of HIF-1α inhibitors. Molecules. 2022;27(11):3426. doi: 10.3390/molecules27113426
Nawangsih CH, Gondhowiardjo S, Haryana SM, Hadisaputro S, Suharti C, Dharmana E, et al. Effect of carbogen to chemoradiation in volume of rectal cancer. Acta Med Iran. 2020;58(1):15-20.
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferiorsurvival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium program. Blood. 2013;121 (20):4021-31. doi: 10.1182/blood-2012-10-460063
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937-47.
Bhatt AP, Jacobs SR, Freemerman AJ, Makowski L, Rathmell JC., Dittmer DP., et al. Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc Nat Academy Sci. 2012;109(29):11818-23.
Holm E, Hagmuller E, Staedt U, Schlickeiser G, Gunther HJ, Leweling H, et al. Substrate balances across colonic carcinomas in humans. Cancer Res. 1995;55:1373–8.
Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation. Oncol Lett. 2012;4:1151-7.
